Health Care
Commentary
Joe Biden Leaves Behind A Disastrous Healthcare Legacy
President Joe Biden’s term will expire on January 20, 2025, when a new president will be inaugurated. He brought his decades-long political career to a close last month when he announced he would not seek re-election. Biden has thrown his support to his vice president, Kamala Harris, in this November’s election. ...
Blog
For Third Year in a Row, PRI Survey Finds Vast Majority of Americans Are Satisfied with their Health Coverage
For Third Year in a Row, PRI Survey Finds Vast Majority of Americans Are Satisfied with their Health Coverage Just 37% Support Government Health Care Takeover SACRAMENTO – For the third year in a row, an overwhelming majority of Americans say they are satisfied with their current health coverage, based ...
Commentary
Obamacare needs to police fraud
Are Obamacare’s exchanges hotbeds of fraud? New research suggests as much. An estimated 4 million to 5 million people have received fully subsidized health insurance by misrepresenting their income. That’s $20 billion lost to bogus enrollments this year. The problem stems from the original design of Obamacare – and the ...
Commentary
Vance Must Put America First on Healthcare
Ohio Sen. J.D. Vance has made quite a splash since arriving in Washington less than two years ago. He’s gone from the junior senator from Ohio and the 96th by seniority to the top of the Republican ticket as Donald Trump’s running mate. Vance has branded himself as an “America First” conservative. ...
Commentary
Kamala Harris’s healthcare record is rotten to the core
Democrats, including former President Barack Obama, have enthusiastically rallied around Vice President Kamala Harris as their presumptive presidential nominee. Voters will not be nearly as enthusiastic about her record on healthcare. Harris stands to President Joe Biden’s left on health policy. If elected, she would almost certainly drag the United States closer to a complete government ...
Commentary
Read the latest on the 340B Drug Pricing Program
Reforming 340B to Serve the Interests of Patients, Not Institutions
By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
Health Care
NEW BRIEF: Washington Must End Physician Price Controls, Reform Medicare Payment System to Prevent Doctor Shortages
SACRAMENTO – A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute finds that artificially low reimbursement rates used by Medicare to contain costs are threatening patient care, and reform is needed to prevent future doctor shortages. Click to download the ...
Commentary
Read about Biden's plan to extend health insurance to DACA
Biden’s Healthcare Amnesty Solves Nothing — and at a Staggering Cost
The Biden administration recently finalized a rule extending subsidized health coverage to approximately 100,000 people without health insurance who entered the United States illegally. These folks are part of the Deferred Action for Childhood Arrivals, or DACA, program — a group sometimes known as “dreamers.” The new rule effectively rewrites ...
Commentary
Fauci Has Only Himself to Blame for His COVID Legacy
“We have seen complete fabrications become some people’s accepted reality,” Dr. Anthony Fauci laments in his new memoir “On Call: A Doctor’s Journey in Public Service.” Surely the good doctor means to speak about his ideological foes, who have long decried the heavy-handed response to COVID-19 that Dr. Fauci symbolizes. But today, ...
Commentary
We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.
Earlier this month, the U.S. Food and Drug Administration approved donanemab, a novel treatment for Alzheimer’s disease that Eli Lilly will sell under the brand name Kisunla. The drug targets amyloid, a type of protein that builds up in the brains of people with the disease. It was shown to slow the ...
Joe Biden Leaves Behind A Disastrous Healthcare Legacy
President Joe Biden’s term will expire on January 20, 2025, when a new president will be inaugurated. He brought his decades-long political career to a close last month when he announced he would not seek re-election. Biden has thrown his support to his vice president, Kamala Harris, in this November’s election. ...
For Third Year in a Row, PRI Survey Finds Vast Majority of Americans Are Satisfied with their Health Coverage
For Third Year in a Row, PRI Survey Finds Vast Majority of Americans Are Satisfied with their Health Coverage Just 37% Support Government Health Care Takeover SACRAMENTO – For the third year in a row, an overwhelming majority of Americans say they are satisfied with their current health coverage, based ...
Obamacare needs to police fraud
Are Obamacare’s exchanges hotbeds of fraud? New research suggests as much. An estimated 4 million to 5 million people have received fully subsidized health insurance by misrepresenting their income. That’s $20 billion lost to bogus enrollments this year. The problem stems from the original design of Obamacare – and the ...
Vance Must Put America First on Healthcare
Ohio Sen. J.D. Vance has made quite a splash since arriving in Washington less than two years ago. He’s gone from the junior senator from Ohio and the 96th by seniority to the top of the Republican ticket as Donald Trump’s running mate. Vance has branded himself as an “America First” conservative. ...
Kamala Harris’s healthcare record is rotten to the core
Democrats, including former President Barack Obama, have enthusiastically rallied around Vice President Kamala Harris as their presumptive presidential nominee. Voters will not be nearly as enthusiastic about her record on healthcare. Harris stands to President Joe Biden’s left on health policy. If elected, she would almost certainly drag the United States closer to a complete government ...
Read the latest on the 340B Drug Pricing Program
Reforming 340B to Serve the Interests of Patients, Not Institutions
By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
NEW BRIEF: Washington Must End Physician Price Controls, Reform Medicare Payment System to Prevent Doctor Shortages
SACRAMENTO – A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute finds that artificially low reimbursement rates used by Medicare to contain costs are threatening patient care, and reform is needed to prevent future doctor shortages. Click to download the ...
Read about Biden's plan to extend health insurance to DACA
Biden’s Healthcare Amnesty Solves Nothing — and at a Staggering Cost
The Biden administration recently finalized a rule extending subsidized health coverage to approximately 100,000 people without health insurance who entered the United States illegally. These folks are part of the Deferred Action for Childhood Arrivals, or DACA, program — a group sometimes known as “dreamers.” The new rule effectively rewrites ...
Fauci Has Only Himself to Blame for His COVID Legacy
“We have seen complete fabrications become some people’s accepted reality,” Dr. Anthony Fauci laments in his new memoir “On Call: A Doctor’s Journey in Public Service.” Surely the good doctor means to speak about his ideological foes, who have long decried the heavy-handed response to COVID-19 that Dr. Fauci symbolizes. But today, ...
We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.
Earlier this month, the U.S. Food and Drug Administration approved donanemab, a novel treatment for Alzheimer’s disease that Eli Lilly will sell under the brand name Kisunla. The drug targets amyloid, a type of protein that builds up in the brains of people with the disease. It was shown to slow the ...
